Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 20
Summary
- Conditions
- Hypertension Pulmonary
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 6 years and 17 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02562235
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Study Director: Bayer Study Director Bayer